Premium
Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer
Author(s) -
Chawla Akhil
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26393
Subject(s) - medicine , neoadjuvant therapy , pancreatic cancer , chemotherapy , oncology , clinical trial , disease , cancer , breast cancer
While the use of neoadjuvant therapy is well‐accepted in the treatment of borderline resectable and locally advanced pancreatic cancers, the benefit of neoadjuvant chemotherapy in patients with resectable disease has been a topic of debate. Recently, key trials evaluating neoadjuvant chemotherapy for resectable pancreatic cancer have reported results. This review describes key clinical trials evaluating the use of preoperative therapy in patients with technically resectable pancreatic cancer with a focus on their contribution to the available evidence.